CAS: 1904-31-0; 1-Methyl-1H-Pyrazol-3-Amine

相似化合物

863504-84-1 21377-09-3 54210-32-1

上下游产品

CAS号75092-34-1 4-Iodo-1-methyl... | CAS号54210-32-1 1-甲基-3-硝基吡唑 | CAS号63425-54-7 3-氯-1-甲基-1H-吡唑 | CAS号146941-72-2 N-2-甲基-3-氨基-4-溴吡唑 | CAS号35149-49-6 1,5-Dimethylpyr... | CAS号151049-87-5 3-溴-1-甲基吡唑 | CAS号64748-43-2 1-methyl-5-phen... | CAS号64748-58-9 5-(4-chlorophen... | CAS号79208-64-3 1-甲基-1,2-二氢吡唑-3-硫酮 | CAS号89088-58-4 5-methylpyrazol... | CAS号915771-05-0 3,5-双(苄氧基)-N-(1... | CAS号92736-43-1 1-methyl-5-(tri...

4-Iodo-1-Methyl-3-Nitropyrazole置于盐酸,Tin(Ll) Chloride体系中,用 水 用作溶剂,化学反应 2.0H,以51%的收率获得n-甲基-3-氨基吡唑
参考文献:Synthesis Of Vicinal Aminoiodo-And (Acetylamino)Iodo-L-Alkylpyrazoles
标题:Synthesis Of Vicinal Aminoiodo-And (Acetylamino)Iodo-L-Alkylpyrazoles
摘要:3-And 5-(Acetylamino)-4-Iodo-1-Alkylpyrazoles Were Obtained By Successive Acylation And Iodination From 3-And 5-Amino-1-Alkylpyrazoles Without Isolating Intermediate (Acetylamino)Pyrazoles. 3-And 5-Iodo-And 3,5-Diiodo-4-Amino-1-Methylpyrazoles Were Synthesized From Appropriate Iodonitropyrazoles By Reduction With Sncl2 In Hcl.
Doi:10.1007/bf01431121

专利信息

专利号:US-11512097-B2
优先权日:2019-11-25
标题 :Heterocyclic compounds as Delta-5 desaturase inhibitors and methods of use
发明人：ALLEN JENNIFER R; BELTRANI MICHELA; BOURBEAU MATTHEW P; DAMYANOVA TEODORA P; LINGARD IAIN; MINATTI ANA E; VINCETTI PAOLO
权利人:AMGEN INC
摘要:The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5Dâ€?). The compounds have a general Formula I n nwherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

专利号:WO-2023072969-A1
优先权日:2021-10-26
标题 :Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
发明人：DEAU EMMANUEL; GEORGE PASCAL; MEIJER LAURENT; MIEGE FRÉDÉRIC; ARCHAMBAUD SYLVIE
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I) wherein A, B, C, D and E are selected from the group consisting of =CH- and -N=, R 2 is selected from a hydrogen atom, a (C 1 -C 4 )alkyl group and a (C 3 -C 6 )cycloalkyl group, R 1 represents a (C 4 -C 6 )alkyl group, a (C 3 -C 8 )cycloalkyl group, a bridged (C 6 -C 10 )cycloalkyl group, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C 1 -C 3 )alkanediyl group, and R' represents, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R'-L- group wherein L is a (C 1 -C 3 )alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits and neuroinflammation associated with Down syndrome, Alzheimer's disease, dementia and/or tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; tendinopathy and osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia, infections and for regulating body temperature.

专利号:US-12398129-B2
优先权日:2020-04-30
标 题 :Imidazolone derivatives as inhibitors of protein kinases in particular DYRK1A, CLK1 and/or CLK4
发明人：DEAU EMMANUEL; GEORGE PASCAL; MEIJER LAURENT; MIEGE FRÉDÉRIC
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R′-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R′ represents a (C3-C8)cycloalkyl group, abridged (C6-C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R′-L- group wherein L is a (C1-C3)alkanediyl group, and R′ is an optionally substituted phenyl group, and wherein R2 represents a hydrogen atom or a (C1-C3)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and viral and unicellular infections and for regulating body temperature.

专利号:EP-3904354-A1
优先权日:2020-04-30
标 题:New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
权利人:PERHA PHARMACEUTICALS
摘要:The present invention relates to a compound of formula (I)n nwherein R 1 represents a (C 1 -C 6 )alkyl group, a spiro(C 5 -C 11 )bicyclic ring, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (Ci-C3)alkanediyl group, and R' represents a (C 3 -C 8 )cycloalkyl group, a bridged (C6-C 10 )cycloalkyl group, a (C 3 -C 8 )heterocycloalkyl group, or a (C 3 -C 8 )heteroaryl group, or a R'-L- group wherein L is a (Ci-C3)alkanediyl group, and R' is a an optionally substituted phenyl group or any of its pharmaceutically acceptable salt. n The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. n It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan-McDermid syndrome; autism; diabetes; regulation of folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and infections and for regulating body temperature.

专利号:US-11731956-B2
优先权日:2018-10-22
标 题:Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors

专利号:US-7427625-B2
优先权日:2006-02-08
标 题 :Substituted thiatriazaacenaphthylene-6-carbonitrile kinase inhibitors
发明人：CONNOLLY PETER J; EMANUEL STUART L; HAYDEN STUART; JOHNSON SIGMOND G; LAGU BHARAT; MIDDLETON STEVEN A; PANDEY NIRANJAN B; POWELL MARK T
权利人:JANSSEN PHARMACEUTICA NV
摘要:The present invention is directed to substituted thiatriazaacenaphthylene-6-carbonitrile compounds of formula (I): n nand forms thereof, their synthesis and use for treating, preventing or ameliorating a chronic or acute protein kinase mediated disease, disorder or condition.